Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes.

Wang W, Cheng X, Buske PJ, Suzich JA, Jin H.

Virology. 2019 Feb;528:144-151. doi: 10.1016/j.virol.2018.12.017. Epub 2019 Jan 5.

PMID:
30616204
2.

Strength in diversity: Understanding the pathways to herpes simplex virus reactivation.

Suzich JB, Cliffe AR.

Virology. 2018 Sep;522:81-91. doi: 10.1016/j.virol.2018.07.011. Epub 2018 Jul 14. Review.

3.

Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.

Zhu Q, Lu B, McTamney P, Palaszynski S, Diallo S, Ren K, Ulbrandt ND, Kallewaard N, Wang W, Fernandes F, Wong S, Svabek C, Moldt B, Esser MT, Jing H, Suzich JA.

J Infect Dis. 2018 Jul 13;218(4):572-580. doi: 10.1093/infdis/jiy189.

PMID:
29617879
4.

Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae.

Pennini ME, De Marco A, Pelletier M, Bonnell J, Cvitkovic R, Beltramello M, Cameroni E, Bianchi S, Zatta F, Zhao W, Xiao X, Camara MM, DiGiandomenico A, Semenova E, Lanzavecchia A, Warrener P, Suzich J, Wang Q, Corti D, Stover CK.

Nat Commun. 2017 Dec 8;8(1):1991. doi: 10.1038/s41467-017-02223-7.

5.

Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.

Durham NM, Mulgrew K, McGlinchey K, Monks NR, Ji H, Herbst R, Suzich J, Hammond SA, Kelly EJ.

Mol Ther. 2017 Aug 2;25(8):1917-1932. doi: 10.1016/j.ymthe.2017.05.006. Epub 2017 Jun 2.

6.

Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4.

Cohen TS, Pelletier M, Cheng L, Pennini ME, Bonnell J, Cvitkovic R, Chang CS, Xiao X, Cameroni E, Corti D, Semenova E, Warrener P, Sellman BR, Suzich J, Wang Q, Stover CK.

JCI Insight. 2017 May 4;2(9). pii: 92774. doi: 10.1172/jci.insight.92774. eCollection 2017 May 4.

7.

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA.

Sci Transl Med. 2017 May 3;9(388). pii: eaaj1928. doi: 10.1126/scitranslmed.aaj1928.

PMID:
28469033
8.

S. aureus blocks efferocytosis of neutrophils by macrophages through the activity of its virulence factor alpha toxin.

Cohen TS, Jones-Nelson O, Hotz M, Cheng L, Miller LS, Suzich J, Stover CK, Sellman BR.

Sci Rep. 2016 Oct 14;6:35466. doi: 10.1038/srep35466.

9.

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.

Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, Vorlaender MK, Bianchi S, Guarino B, De Marco A, Vanzetta F, Agatic G, Foglierini M, Pinna D, Fernandez-Rodriguez B, Fruehwirth A, Silacci C, Ogrodowicz RW, Martin SR, Sallusto F, Suzich JA, Lanzavecchia A, Zhu Q, Gamblin SJ, Skehel JJ.

Cell. 2016 Jul 28;166(3):596-608. doi: 10.1016/j.cell.2016.05.073. Epub 2016 Jul 21.

10.

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease.

Tkaczyk C, Hamilton MM, Sadowska A, Shi Y, Chang CS, Chowdhury P, Buonapane R, Xiao X, Warrener P, Mediavilla J, Kreiswirth B, Suzich J, Stover CK, Sellman BR.

MBio. 2016 Jun 28;7(3). pii: e00528-16. doi: 10.1128/mBio.00528-16.

11.

1918 Influenza receptor binding domain variants bind and replicate in primary human airway cells regardless of receptor specificity.

Davis AS, Chertow DS, Kindrachuk J, Qi L, Schwartzman LM, Suzich J, Alsaaty S, Logun C, Shelhamer JH, Taubenberger JK.

Virology. 2016 Jun;493:238-46. doi: 10.1016/j.virol.2016.03.025. Epub 2016 Apr 11.

12.

Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.

Cheng X, Wang W, Xu Q, Harper J, Carroll D, Galinski MS, Suzich J, Jin H.

J Virol. 2016 May 12;90(11):5343-5352. doi: 10.1128/JVI.00136-16. Print 2016 Jun 1.

13.

Staphylococcus aureus α toxin potentiates opportunistic bacterial lung infections.

Cohen TS, Hilliard JJ, Jones-Nelson O, Keller AE, O'Day T, Tkaczyk C, DiGiandomenico A, Hamilton M, Pelletier M, Wang Q, Diep BA, Le VT, Cheng L, Suzich J, Stover CK, Sellman BR.

Sci Transl Med. 2016 Mar 9;8(329):329ra31. doi: 10.1126/scitranslmed.aad9922.

PMID:
26962155
14.

MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model.

Hua L, Cohen TS, Shi Y, Datta V, Hilliard JJ, Tkaczyk C, Suzich J, Stover CK, Sellman BR.

Antimicrob Agents Chemother. 2015 Aug;59(8):4526-32. doi: 10.1128/AAC.00510-15. Epub 2015 May 18.

15.

Correction for Hao et al., Infection and propagation of human rhinovirus C in human airway epithelial cells.

Hao W, Bernard K, Patel N, Ulbrandt N, Feng H, Svabek C, Wilson S, Stracener C, Wang K, Suzich J, Blair W, Zhu Q.

J Virol. 2015 Apr;89(7):4041. doi: 10.1128/JVI.00119-15. No abstract available.

16.

Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease.

Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, Stover CK, Sellman BR.

MBio. 2015 Feb 17;6(1):e02272-14. doi: 10.1128/mBio.02272-14.

17.

Validation of normal human bronchial epithelial cells as a model for influenza A infections in human distal trachea.

Davis AS, Chertow DS, Moyer JE, Suzich J, Sandouk A, Dorward DW, Logun C, Shelhamer JH, Taubenberger JK.

J Histochem Cytochem. 2015 May;63(5):312-28. doi: 10.1369/0022155415570968. Epub 2015 Jan 20.

18.

A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.

DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK.

Sci Transl Med. 2014 Nov 12;6(262):262ra155. doi: 10.1126/scitranslmed.3009655.

19.

Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model.

Hilliard JJ, Datta V, Tkaczyk C, Hamilton M, Sadowska A, Jones-Nelson O, O'Day T, Weiss WJ, Szarka S, Nguyen V, Prokai L, Suzich J, Stover CK, Sellman BR.

Antimicrob Agents Chemother. 2015 Jan;59(1):299-309. doi: 10.1128/AAC.03918-14. Epub 2014 Oct 27.

20.

A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head.

Benjamin E, Wang W, McAuliffe JM, Palmer-Hill FJ, Kallewaard NL, Chen Z, Suzich JA, Blair WS, Jin H, Zhu Q.

J Virol. 2014 Jun;88(12):6743-50. doi: 10.1128/JVI.03562-13. Epub 2014 Apr 2.

21.

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.

Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, Robbins P, Ulbrandt N, Suzich J, Green J, Patera AC, Blair W, Krishnan S, Hotchkiss R.

Crit Care. 2014 Jan 4;18(1):R3. doi: 10.1186/cc13176.

22.

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.

Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP; Motavizumab Study Group.

Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240.

PMID:
24356256
23.

Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia.

Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR.

Antimicrob Agents Chemother. 2014;58(2):1108-17. doi: 10.1128/AAC.02190-13. Epub 2013 Dec 2.

24.

Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model.

Tkaczyk C, Hamilton MM, Datta V, Yang XP, Hilliard JJ, Stephens GL, Sadowska A, Hua L, O'Day T, Suzich J, Stover CK, Sellman BR.

PLoS One. 2013 Oct 2;8(10):e75103. doi: 10.1371/journal.pone.0075103. eCollection 2013.

25.

Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays.

Deming DJ, Patel N, McCarthy MP, Mishra L, Shapiro AM, Suzich JA.

Pediatr Infect Dis J. 2013 Oct;32(10):1144-6. doi: 10.1097/INF.0b013e31829561dd.

PMID:
23584584
26.

Roadblocks to translational challenges on viral pathogenesis.

Deeks S, Drosten C, Picker L, Subbarao K, Suzich J.

Nat Med. 2013 Jan;19(1):30-4. doi: 10.1038/nm.3050.

PMID:
23296014
27.

Infection and propagation of human rhinovirus C in human airway epithelial cells.

Hao W, Bernard K, Patel N, Ulbrandt N, Feng H, Svabek C, Wilson S, Stracener C, Wang K, Suzich J, Blair W, Zhu Q.

J Virol. 2012 Dec;86(24):13524-32. doi: 10.1128/JVI.02094-12. Epub 2012 Oct 3. Erratum in: J Virol. 2015 Apr;89(7):4041.

28.

Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening.

DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P, Minter R, Camara MM, Venkatraman V, Macgill RS, Lin J, Wang Q, Keller AE, Bonnell JC, Tomich M, Jermutus L, McCarthy MP, Melnick DA, Suzich JA, Stover CK.

J Exp Med. 2012 Jul 2;209(7):1273-87. doi: 10.1084/jem.20120033. Epub 2012 Jun 25.

29.

Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.

Zhu Q, Patel NK, McAuliffe JM, Zhu W, Wachter L, McCarthy MP, Suzich JA.

J Infect Dis. 2012 Feb 15;205(4):635-8. doi: 10.1093/infdis/jir790. Epub 2011 Dec 19.

PMID:
22184728
30.

Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs.

Sow FB, Gallup JM, Krishnan S, Patera AC, Suzich J, Ackermann MR.

Respir Res. 2011 Aug 9;12:106. doi: 10.1186/1465-9921-12-106.

31.

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.

Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.

J Infect Dis. 2011 Mar 1;203(5):674-82. doi: 10.1093/infdis/jiq100. Epub 2011 Jan 5.

32.

Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs.

Sow FB, Gallup JM, Olivier A, Krishnan S, Patera AC, Suzich J, Ackermann MR.

Am J Physiol Lung Cell Mol Physiol. 2011 Jan;300(1):L12-24. doi: 10.1152/ajplung.00169.2010. Epub 2010 Oct 8.

33.

Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model.

Hamelin ME, Gagnon C, Prince GA, Kiener P, Suzich J, Ulbrandt N, Boivin G.

Antiviral Res. 2010 Oct;88(1):31-7. doi: 10.1016/j.antiviral.2010.07.001. Epub 2010 Jul 7.

PMID:
20619294
34.

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.

Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.

Pediatr Infect Dis J. 2009 Sep;28(9):835-7. doi: 10.1097/INF.0b013e3181a165e4.

PMID:
19636278
35.

Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus.

Ulbrandt ND, Ji H, Patel NK, Barnes AS, Wilson S, Kiener PA, Suzich J, McCarthy MP.

J Gen Virol. 2008 Dec;89(Pt 12):3113-8. doi: 10.1099/vir.0.2008/005199-0.

36.

Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis.

Reed JL, Brewah YA, Delaney T, Welliver T, Burwell T, Benjamin E, Kuta E, Kozhich A, McKinney L, Suzich J, Kiener PA, Avendano L, Velozo L, Humbles A, Welliver RC Sr, Coyle AJ.

J Infect Dis. 2008 Dec 15;198(12):1783-93. doi: 10.1086/593173.

PMID:
18980502
37.

Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells.

d'Argouges S, Wissing S, Brandl C, Prang N, Lutterbuese R, Kozhich A, Suzich J, Locher M, Kiener P, Kufer P, Hofmeister R, Baeuerle PA, Bargou RC.

Leuk Res. 2009 Mar;33(3):465-73. doi: 10.1016/j.leukres.2008.08.025. Epub 2008 Oct 2.

PMID:
18835037
38.

The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice.

Hamelin ME, Couture C, Sackett M, Kiener P, Suzich J, Ulbrandt N, Boivin G.

Antivir Ther. 2008;13(1):39-46.

PMID:
18389897
39.

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct.

Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, Prang N, Bargou R, Suzich J, Baeuerle PA, Hofmeister R.

Cancer Immunol Immunother. 2007 Oct;56(10):1551-63. Epub 2007 Feb 20.

PMID:
17310380
40.

Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.

Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, Donacki NE, Folliot K, Barnes AS, Senthil K, Wilson S, Chen M, Clarke L, MacPhail M, Li J, Woods RM, Coelingh K, Reed JL, McCarthy MP, Pfarr DS, Osterhaus AD, Fouchier RA, Kiener PA, Suzich JA.

J Virol. 2006 Aug;80(16):7799-806.

41.

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT, Dubin G, Wettendorff MA.

Vaccine. 2006 Aug 14;24(33-34):5937-49. Epub 2006 Jun 19.

PMID:
16828940
43.

Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.

Damschroder MM, Kozhich AA, Woods RM, Cheng L, Mullikin BA, Wilson SD, Ulbrandt ND, Bachy CM, Wu H, Suzich JA, Kiener PA, Dall'Acqua WF, White WI.

Mol Immunol. 2004 Aug;41(10):985-1000.

PMID:
15302161
44.

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM.

J Infect Dis. 2004 Sep 1;190(5):975-8. Epub 2004 Jul 27.

PMID:
15295704
45.

Human papillomavirus type 45 propagation, infection, and neutralization.

McLaughlin-Drubin ME, Wilson S, Mullikin B, Suzich J, Meyers C.

Virology. 2003 Jul 20;312(1):1-7.

46.

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.

Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC.

J Infect Dis. 2001 May 15;183(10):1485-93. Epub 2001 Apr 24.

PMID:
11319684
47.

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL.

Vaccine. 1999 Apr 23;17(17):2129-35.

PMID:
10367945
48.

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.

White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, Suzich JA.

J Virol. 1999 Jun;73(6):4882-9.

49.

Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL.

J Virol. 1998 Jul;72(7):6151-4.

50.

In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA.

J Virol. 1998 Feb;72(2):959-64.

Supplemental Content

Loading ...
Support Center